Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell, and is a form of unsealed source radiotherapy. In cancer therapy, an antibody with specificity for a tumor-associated antigen delivers a lethal dose of radiation to tumor cells; because the antibody binds specifically to that antigen, the dose delivered to the tumor increases while the dose to normal tissue decreases. The technique requires the tumor cell to express an antigen that is unique to the tumor or otherwise inaccessible in normal cells.
Facts
FAQs
Which cancers has radioimmunotherapy been approved to treat?
Ibritumomab tiuxetan (Zevalin) is approved for B-cell follicular non-Hodgkin lymphoma in certain adults.
A well known example is ibritumomab tiuxetan, sold in the United States under the brand name Zevalin. The National Cancer Institute lists it as approved to treat B-cell follicular non-Hodgkin lymphoma in adults with relapsed or refractory low-grade disease, or who are having a complete or partial response to first-line chemotherapy. It is also being studied in other types of cancer.
Connections
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
Radioimmunotherapy (Wikipedia)
https://en.wikipedia.org/wiki/Radioimmunotherapy, lead sectionQuote, https://en.wikipedia.org/wiki/Radioimmunotherapy, lead section
Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.